Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease

Poole, Phillippa; Chong, Jimmy; Cates, Christopher J

doi:10.1002/14651858.cd001287.pub5

Cited by 80 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mucolytics A Cochrane review of 34 studies showed that a mucolytic therapy in patients with COPD increases the likelihood of being exacerbation free [67], compared with placebo. The number needed to treat (to keep an additional patient free from exacerbations for an average of 10 months) was eight.…”

Section: Prophylactic Antibioticsmentioning

confidence: 99%

Exacerbations of COPD

2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, longterm antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.

show abstract

Section: Prophylactic Antibioticsmentioning

confidence: 99%

Exacerbations of COPD

2018

View full text Add to dashboard Cite

show abstract

“…170,171 Due to the heterogeneity of studied populations, treatment dosing and concomitant treatments, currently available data do not allow one to identify precisely the potential target population for antioxidant agents in COPD.…”

Section: Mucolytic (Mucokinetics Mucoregulators) and Antioxidant Agementioning

confidence: 99%

Exploration de la fonction pulmonaire par spirométrie

Bridevaux¹,

Petitpierre²,

Bloch³

et al. 2018

Swiss Med Forum

View full text Add to dashboard Cite

“…Было сделано заключение, что долгосрочная терапия на протяжении 6 месяцев хрониче-ского бронхита Миртолом стандартизированным снижает частоту и интенсивность рецидивов [15]. Данное клиниче-ское исследование учитывалось в Кохрановском цен-тральном регистре контролируемых исследований среди отобранных 34 из нескольких сотен работ и одно из немногих получило 4 из 5 возможных баллов при оценке качества [16].…”

Section: хронический бронхитunclassified